FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981739486> ?p ?o ?g. }

• W2981739486 abstract "Abstract Background The growing opioid epidemic is driving increasing rates of hepatitis C virus (HCV) infections in the United States. HCV transmission is most frequently attributed to unsafe injection behaviors, but can occur via other unsafe drug use and sexual behaviors. Differences in demographics, HCV rates and associated risk factors in non-injecting PWUD (NIPWUD), compared with people who inject drugs (PWID) must be understood in order to target elimination strategies. Methods Change is Philadelphia’s program to eliminate HCV among PWUD and enrollment includes HCV testing, linkage services, and an interviewer-administered survey including risk behaviors and healthcare engagement. This interim analysis includes the first 835 enrollees that identified as PWUD. For this analysis, PWID are enrollees who indicated ever injecting drugs and those who had not are NIPWUD. Results Among enrollees, 76% (N = 637) reported ever injecting drugs. PWIDs were younger and non-Hispanic (NH) white while NIPWUD were older and NH Black (age: P = 0.003; race/ethnicity: P < 0.0001). NIPWUDs had a high seropositivity rate though significantly lower than PWIDs (24% vs. 85%, respectively; P < 0.0001). Among PWID enrollees, 94% (N = 596) ever snorted. Of enrollees, 63% (N = 124) of NIPWUD and 56% (N = 356) of PWID identified having a PCP (P =0.07). PWIDs are more likely than NIPWUD to have overdosed (OD) (40% vs. 9%; P < 0.0001) though high rates of both groups ever witnessed an OD (84% vs. 67%, respectively). While 80% (N = 105) of NIPWUDs know how to use Narcan, 60% (N = 79) carry it, {94% (N = 503) and 71%(N = 381) in PWID, respectively}. NIPWUDs are more likely to be interested in drug treatment (P < 0.0001) and to have received it in the last 12 months (P = 0.0008). Conclusion Notable HCV infection exists among non-injecting PWUD reinforcing the need for harm reduction counseling and access to drug use equipment used for smoking and snorting. NIPWUD may be able to access drug and HCV treatment through PCPs and fatal ODs may be prevented by ensuring NIPWUDs have access to Narcan. In addition, PWID are likely to snort as well and should be counseled on non-injecting harm reduction methods. To succeed in micro elimination among PWUD, a focus on NIPWUDs as well as PWIDs is necessary to mitigate transmission of HCV. Disclosures All authors: No reported disclosures." @default.
• W2981739486 created "2019-11-01" @default.
• W2981739486 creator A5003269100 @default.
• W2981739486 creator A5028249784 @default.
• W2981739486 creator A5029759530 @default.
• W2981739486 creator A5036887186 @default.
• W2981739486 creator A5039404252 @default.
• W2981739486 creator A5076631443 @default.
• W2981739486 date "2019-10-01" @default.
• W2981739486 modified "2023-09-24" @default.
• W2981739486 title "316. Hepatitis C and Engagement in Health Care Among Persons Who Inject Drugs and Persons Who Use Non-Injection Drugs, Philadelphia" @default.
• W2981739486 doi "https://doi.org/10.1093/ofid/ofz360.389" @default.
• W2981739486 hasPublicationYear "2019" @default.
• W2981739486 type Work @default.
• W2981739486 sameAs 2981739486 @default.
• W2981739486 citedByCount "0" @default.
• W2981739486 crossrefType "journal-article" @default.
• W2981739486 hasAuthorship W2981739486A5003269100 @default.
• W2981739486 hasAuthorship W2981739486A5028249784 @default.
• W2981739486 hasAuthorship W2981739486A5029759530 @default.
• W2981739486 hasAuthorship W2981739486A5036887186 @default.
• W2981739486 hasAuthorship W2981739486A5039404252 @default.
• W2981739486 hasAuthorship W2981739486A5076631443 @default.
• W2981739486 hasBestOaLocation W29817394861 @default.
• W2981739486 hasConcept C126322002 @default.
• W2981739486 hasConcept C177713679 @default.
• W2981739486 hasConcept C2776455275 @default.
• W2981739486 hasConcept C2780749119 @default.
• W2981739486 hasConcept C3013748606 @default.
• W2981739486 hasConcept C3017768595 @default.
• W2981739486 hasConcept C512399662 @default.
• W2981739486 hasConcept C71924100 @default.
• W2981739486 hasConcept C74909509 @default.
• W2981739486 hasConceptScore W2981739486C126322002 @default.
• W2981739486 hasConceptScore W2981739486C177713679 @default.
• W2981739486 hasConceptScore W2981739486C2776455275 @default.
• W2981739486 hasConceptScore W2981739486C2780749119 @default.
• W2981739486 hasConceptScore W2981739486C3013748606 @default.
• W2981739486 hasConceptScore W2981739486C3017768595 @default.
• W2981739486 hasConceptScore W2981739486C512399662 @default.
• W2981739486 hasConceptScore W2981739486C71924100 @default.
• W2981739486 hasConceptScore W2981739486C74909509 @default.
• W2981739486 hasLocation W29817394861 @default.
• W2981739486 hasLocation W29817394862 @default.
• W2981739486 hasOpenAccess W2981739486 @default.
• W2981739486 hasPrimaryLocation W29817394861 @default.
• W2981739486 isParatext "false" @default.
• W2981739486 isRetracted "false" @default.
• W2981739486 magId "2981739486" @default.
• W2981739486 workType "article" @default.